Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

Journal of the National Cancer Institute

Volumn 89, Issue 21, 1997, Pages 1595-1601

  Irvine, Kari R ^a   Chamberlain, Ronald S ^a,c   Shulman, Eliza P ^a   Surman, Deborah R ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CANCER VACCINE; RECOMBINANT VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOMA; COWPOX VIRUS; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; FOWLPOX VIRUS; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; PLASMID; SURVIVAL; VACCINATION;

EID: 0030663697     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.21.1595     Document Type: Article

References (30)

1. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today 1995;16:334-6.
2. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996;88:16355-44.
3. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996;156:238-45.
4. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154:4685-92.
5. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
6. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337: 567-72.
7. Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992;166:244-52.
8. Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993;11:1154-8.
9. Fuller DH, Haynes JR. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994;10:1433-41.
10. Earl PL, Moss B. Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG. South JA, et al., editors. Current protocols in molecular biology. New York: Green Publishing Associates, 1994;16.15.1-16.18.10.
11. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996; 156:3357-65.
12. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
13. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H, Hengartner H. On immunological memory. Annu Rev Immunol 1996;14: 333-67.
14. Bruno L, Kirberg J, von Boehmer H. On the cellular basis of immunological T cell memory. Immunity 1995;2:37-43.
15. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med 1991;174:969-74.
16. Kundig TM, Bachmann MF, Ohashi PS, Pircher H, Hengartner H, Zinkernagel RM. On T cell memory: arguments for antigen dependence. Immunol Rev 1996;150:63-90.
17. Corny RM, LoBuglio AF, Kantor J, Schlom J, Loechel F, Moore SE, et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994;54:1164-8.
18. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
19. Estin CD, Stevenson US, Plowman GD, Hu SL, Sridhar P, Hellstrom I, et al. Recombinant vaccinia virus against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A 1988;85:1052-6.
20. Murata K, Garcia-Sastre A, Tsuji M, Rodrigues M, Rodriguez D, Rodriguez JR, et al. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 1996;173:96-107.
21. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-68.
22. Battegay M, Moskophidis D, Waldner H, Brundler MA, Fung-Leung WP, Mak TW, et al. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells [published erratum appears in J Immunol 1994;152:1635]. J Immunol 1993;151:5408-15.
23. Deng Y, Yewdell JW, Eisenlohr LC, Bennink JR. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 1997;158:1507-15.
24. Oldstone MB, Lewicki H, Borrow P, Hudrisier D, Gairin J. Discriminated selection among viral peptides with the appropriate anchor residues: implication for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J Virol 1995;69:7423-9.
25. b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol 1995;69:6665-77.
26. Skinner MA, Moore JB, Binns MM, Smith GL, Boursnell ME. Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes. J Gen Virol 1994;75:2495-8.
27. Tartaglia J, Winslow J, Goebel S, Johnson GP, Taylor J, Paoletti E. Nucleotide sequence analysis of a 10.5 kbp HindIII fragment of fowlpox virus: relatedness to the central portion of the vaccinia virus HindIII D region. J Gen Virol 1990;71:1517-24.
28. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
29. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
30. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nano-gram quantities of DNA. Vaccine 1995; 13:1427-30.